Cancer Center Clínica Universidad de Navarra (CCUN)
Centro clínico de la Universidad de Navarra
![Foto de Cancer Center Clínica Universidad de Navarra (CCUN)](/img/uploaded/C185D7383C9859310EFAE5D78F321270.jpg)
![Foto de Hospital Universitario de Salamanca](/img/noimage_org.png)
Hospital Universitario de Salamanca
Salamanca, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario de Salamanca (855)
2024
-
A Simple Frailty Score Predicts Survival and Early Mortality in Systemic AL Amyloidosis
Cancers, Vol. 16, Núm. 9
-
Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma
Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096
-
Chromosomal breaks: another differential gap between early-onset and late-onset colorectal cancers
British Journal of Surgery, Vol. 111, Núm. 3
-
Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma
Advances in Therapy, Vol. 41, Núm. 4, pp. 1576-1593
-
Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee
The Lancet Oncology
-
Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes
Nature Communications, Vol. 15, Núm. 1
-
Improving the Access of Highly Sensitized Patients to Kidney Transplantation From Deceased Donors: The Spanish PATHI Program With Allocation Based on the Virtual Crossmatch
Transplantation, Vol. 108, Núm. 3, pp. 787-801
-
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma
The Lancet Oncology, Vol. 25, Núm. 5, pp. e205-e216
-
Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma
Blood, Vol. 143, Núm. 7, pp. 597-603
-
Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling
Haematologica, Vol. 109, Núm. 3, pp. 877-887
-
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection
Haematologica, Vol. 109, Núm. 6, pp. 1909-1917
-
Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma
Blood cancer discovery, Vol. 5, Núm. 3, pp. 146-152
-
Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia
American Journal of Hematology, Vol. 99, Núm. 4, pp. 586-595
-
Single-cell transcriptional profile of CD34+ hematopoietic progenitor cells from del(5q) myelodysplastic syndromes and impact of lenalidomide
Nature Communications, Vol. 15, Núm. 1
-
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study
Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 3, pp. 194-202
-
The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression
Blood cancer journal, Vol. 14, Núm. 1, pp. 74
-
Uric Acid and acute kidney injury in high-risk patients for developing Acute Kidney Injury undergoing cardiac surgery: a prospective multicenter study
Revista Espanola de Anestesiologia y Reanimacion
2023
-
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
New England Journal of Medicine, Vol. 389, Núm. 4, pp. 335-347
-
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
Blood cancer journal
-
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 3019-3031